Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027
Reuters
Sep 30, 2025
Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027
**Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - Sutro Biopharma Inc. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.